Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Definium Therapeutics (NASDAQ:DFTX) had its target price upped by analysts at Royal Bank Of Canada from $66.00 to $70.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price would indicate a potential upside of 103.19% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Piper Sandler reiterated an “overweight” rating and set a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Robert W. Baird increased their price objective on shares of Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. JPMorgan Chase & Co. assumed coverage on shares of Definium Therapeutics in a report on Friday, October 9th. They set an “overweight” rating and a $84.00 price objective for the company. Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Canaccord Genuity Group set a $78.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $66.24.

Definium Therapeutics Stock Performance

Shares of NASDAQ:DFTX traded down $0.94 during trading on Tuesday, hitting $34.45. 291,913 shares of the stock were exchanged, compared to its average volume of 2,215,520. Definium Therapeutics has a 1-year low of $10.46 and a 1-year high of $49.70. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of -10.04 and a beta of 2.23. The company’s fifty day simple moving average is $36.49 and its 200-day simple moving average is $30.05. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.09. Sell-side analysts expect that Definium Therapeutics will post -3.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other Definium Therapeutics news, CFO Brandi Roberts sold 3,377 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the transaction, the chief financial officer owned 394,528 shares in the company, valued at approximately $14,427,888.96. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the business’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the completion of the transaction, the chief executive officer directly owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. This represents a 1.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,098 shares of company stock valued at $2,626,115 in the last 90 days. Insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP acquired a new position in Definium Therapeutics during the 2nd quarter worth about $138,755,000. Bank of New York Mellon Corp grew its holdings in Definium Therapeutics by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after acquiring an additional 24,349 shares during the last quarter. Russell Investments Group Ltd. increased its position in Definium Therapeutics by 116.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 331,702 shares of the company’s stock valued at $12,647,000 after acquiring an additional 178,225 shares in the last quarter. Royce & Associates LP increased its position in Definium Therapeutics by 20.1% in the 3rd quarter. Royce & Associates LP now owns 250,547 shares of the company’s stock valued at $9,536,000 after acquiring an additional 41,996 shares in the last quarter. Finally, Aberdeen Group plc increased its position in Definium Therapeutics by 10.0% in the 3rd quarter. Aberdeen Group plc now owns 192,415 shares of the company’s stock valued at $7,323,000 after acquiring an additional 17,415 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said it will present Phase 3 DT120 data at the NEI Congress. The presentations could raise awareness of the late-stage program, although no results or conclusions are provided in the announcement. Definium Announces DT120 Phase 3 Data Presentations at NEI Congress
• Positive Sentiment: For the third quarter, Definium reported a loss of $0.46 per share, beating the consensus estimate of a $0.55 loss by $0.09. The earnings surprise may support sentiment, though the company remains loss-making. Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
• Neutral Sentiment: Definium granted options to buy 269,800 shares to ten new employees. The awards support hiring, while adding potential share dilution; the announcement does not indicate a material near-term financial impact. Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.